Development of a novel treatment for endometriosis by focusing on the endometrial microenvironment.

2023 Fiscal Year Final Research Report

• Project/Area Number: 22K16832
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56040:Obstetrics and gynecology-related
• Research Institution: Nagoya University
• Principal Investigator: MURAOKA AYAKO 名古屋大学, 医学部附属病院, 助教 (40930269)
• Project Period (FY): 2022-04-01 – 2024-03-31
• Keywords: 子宮内膜症 / 子宮内膜線維芽細胞 / 子宮内細菌

Outline of Final Research Achievements

In order to investigate the pathogenesis of endometriosis, we focused on transgelin (TAGLN), which is highly expressed in the eutopic endometrium of patients with endometriosis, and aimed to elucidate the pathogenesis of endometriosis and develop a novel treatment for endometriosis. We also investigated the involvement of IL-6 as a myokine in the pathogenesis of endometriosis. In vivo model, using mouse models of endometriosis, we sought a treatment method to suppress the expression of TAGLN in endometrial fibroblasts and to attenuate the onset of endometriosis.

Free Research Field

子宮内膜症

Academic Significance and Societal Importance of the Research Achievements

子宮内膜症の病態解明に迫り、子宮内膜内の線維芽細胞に高発現するTAGLNに着目し、その上流の分子動態機構を明らかにすることで子宮内膜症への子宮内膜内細菌の関与を見出したことは、妊娠を希望する子宮内膜症患者にとって手術や偽閉経療法を回避できる新規治療戦略を打ち出す緒となったと考えられる。社会的にも罹患率の高い子宮内膜症について新規治療戦略が望めれば少子化対策など社会貢献となる価値があると考える。